
Pharma Pulse 7/12/24: The Weight-Loss Gold Rush, GSK Begins Shipping 24-25 Influenza Vaccines & more
The latest news for pharma industry insiders.
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
In pediatric and adult patients, the top 3 surgical procedures accounted for the highest share of opioid prescriptions, indicating a need for better opioid prescription management and greater awareness of the possible opioid-related adverse events that can stem from prescriptions of the drug.
Chains experiment with machine helpers like Flippy, Chippy and Autocado as they face increasing labor costs.
GSK plc announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration.
Today’s patient support programs require a tailored approach that recognizes the unique journeys patients undergo to access their medications. In his latest article with Pharmaceutical Commerce Magazine, Gajanan Kulkarni, Vice President of Product Management at CoverMyMeds, discusses ways medication access barriers can be removed by leveraging new technologies, expanding network connections, and tapping into the power of human interactions. Read more: https://bit.ly/3WgZ79B.
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

